Skip to content

Exelixis EXEL Unrealized Losses on Investments (Before Tax)

Unrealized Losses on Investments (Before Tax) at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$2.73M+58.3%
Summit Therapeutics logo
Summit TherapeuticsSMMT
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
Amgen logo
AmgenAMGN

Other financials

Income statement

See full
Revenue$610.8M+10.0%
Gross profit$590.9M+10.2%
Operating income$251.3M+34.5%
Net income$210.5M+31.9%
EPS (diluted)$0.79+43.6%

Balance sheet

See full
Cash & equivalents$226.2M+23.1%
Total debt$169.5M-9.4%
Total equity$1.9B-9.2%
Total assets$2.6B-8.6%

Cash flow

See full
Operating cash flow$251.8M+19.1%
CapEx$1.5M-48.9%
Free cash flow$250.3M+20.1%

Valuation

See full
Market cap$13.05B+10.1%
Enterprise value$12.99B+9.5%
P/E15.7×-2.8×
P/S5.5×+0.3×

Profitability

See full
Gross margin96.4%-0.3pp
Operating margin39.4%+6.3pp
Net margin35.1%+7.1pp
FCF margin38.6%+2.9pp

Returns & leverage

See full
Return on equity41%+10.8pp
Debt / equity0.1×0.0×
Current ratio3.3×-0.2×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.

The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exelixis's unrealized losses on investments (before tax).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Exelixis's unrealized losses on investments (before tax)?
Exelixis (EXEL) reported unrealized losses on investments (before tax) of $1.96M in Q1 2026.
How has Exelixis's unrealized losses on investments (before tax) changed year-over-year?
Exelixis's unrealized losses on investments (before tax) increased by 104.4% year-over-year, from $958K to $1.96M.
What is the long-term trend for Exelixis's unrealized losses on investments (before tax)?
Over 5 years (2020 to 2025), Exelixis's unrealized losses on investments (before tax) has grown at a 25.9% compound annual growth rate (CAGR), from $12K to $38K.